Kinnate Biopharma Inc. (KNTE) NASDAQ
$9.05 -0.88 (-8.86%)
Market Cap: $397.98M
As of 05/25/22 04:00 PM EDT. Market closed.
Kinnate Biopharma Inc. (KNTE) NASDAQ
$9.05 -0.88 (-8.86%)
Market Cap: $397.98M
As of 05/25/22 04:00 PM EDT. Market closed.
Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, ... read more
Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors. read less
Open in:
Open in:
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Williams Richard Thomas | Chief Medical Officer | Mar 14, 2022 | Buy | $8.37 | 25,000 | 209,250 | 42,333 | Mar 15, 2022, 05:01 PM |
| Williams Richard Thomas | Chief Medical Officer | Mar 11, 2022 | Buy | $8.64 | 15,000 | 129,600 | 17,333 | Mar 15, 2022, 05:01 PM |
| GORDON CARL L | Director | Feb 15, 2022 | Buy | $9.96 | 9,000 | 89,640 | 3,509,030 | Feb 15, 2022, 09:51 PM |
| GORDON CARL L | Director | Feb 14, 2022 | Buy | $9.95 | 30,700 | 305,486 | 3,500,030 | Feb 15, 2022, 09:51 PM |
| GORDON CARL L | Director | Feb 11, 2022 | Buy | $10.22 | 156,000 | 1,594,320 | 3,469,330 | Feb 15, 2022, 09:51 PM |
| ORBIMED ADVISORS LLC | Director | Feb 11, 2022 | Buy | $10.22 | 156,000 | 1,594,320 | 3,469,330 | Feb 15, 2022, 09:42 PM |
| ORBIMED ADVISORS LLC | Director | Feb 15, 2022 | Buy | $9.96 | 9,000 | 89,640 | 3,509,030 | Feb 15, 2022, 09:42 PM |
| ORBIMED ADVISORS LLC | Director | Feb 14, 2022 | Buy | $9.95 | 30,700 | 305,486 | 3,500,030 | Feb 15, 2022, 09:42 PM |
| Tananbaum James B. | Director | Dec 03, 2020 | Buy | $20.00 | 1,000,000 | 20,000,000 | 500,000 | Dec 04, 2020, 09:39 PM |
| Foresite Capital Management IV, LLC | 10% Owner | Dec 03, 2020 | Option Exercise | $20.00 | 1,000,000 | 20,000,000 | 500,000 | Dec 04, 2020, 08:57 PM |
| ORBIMED ADVISORS LLC | Director | Dec 02, 2020 | Buy | $20.00 | 750,000 | 15,000,000 | 450,000 | Dec 04, 2020, 06:11 PM |
| GORDON CARL L | Director | Dec 02, 2020 | Buy | $20.00 | 750,000 | 15,000,000 | 450,000 | Dec 04, 2020, 05:13 PM |
| Owner | Relationship | Date | Value($) |
| Williams Richard Thomas | Chief Medical Officer | 03/14/2022 | 209,250 |
| Williams Richard Thomas | Chief Medical Officer | 03/11/2022 | 129,600 |
| GORDON CARL L | Director | 02/15/2022 | 89,640 |
| GORDON CARL L | Director | 02/14/2022 | 305,486 |
| GORDON CARL L | Director | 02/11/2022 | 1,594,320 |
| ORBIMED ADVISORS LLC | Director | 02/11/2022 | 1,594,320 |
| ORBIMED ADVISORS LLC | Director | 02/15/2022 | 89,640 |
| ORBIMED ADVISORS LLC | Director | 02/14/2022 | 305,486 |
| Tananbaum James B. | Director | 12/03/2020 | 20,000,000 |
| Foresite Capital Management IV, LLC | 10% Owner | 12/03/2020 | 20,000,000 |
| ORBIMED ADVISORS LLC | Director | 12/02/2020 | 15,000,000 |
| GORDON CARL L | Director | 12/02/2020 | 15,000,000 |
Period of Report: 12/31/2021
10-K/10-Q Filings: View